

FORM PTO-1449

U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICEATTY. DOCKET
NO: SO3078/4APPLICATION NO.:
10/016,146INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

INVENTOR:
Cunningham, et. al.

Filed: 12/10/01

Group: 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,677,111	6/30/87	Haga, et. al.	514	274	10/1/85
	A2	5,256,812	10/26/93	Alig, et. al.	560	035	9/6/91
	A3	5,518,735	5/21/96	Sturzbecher, et. al.	424	449	11/15/91
	A4	5,753,230	5/19/98	Brooks	424	158.1	3/18/94
	A5	5,766,591	6/16/98	Brooks	424	184.1	12/30/94
	A6	6,013,651	1/11/00	Rogers	514	269	<i>DUPLICATED</i>

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
B1	WO98/31359	7/23/98	WO					
B2	WO98/14192	4/9/98	WO					
B3	WO97/08145	03/06/97	WO					
B4	AU-A-57984/94	10/6/94	Australia					
B5	AU-A-79090/94	6/8/95	Australia					
B6	2,059,857	7/25/92	Canada					
B7	2,134,418	4/29/95	Canada					
B8	0,343,893 A1	11/29/89	EPO					
B9	0,343,894 A1	11/29/89	EPO					
B10	0,478,328 A1	4/1/92	EPO					
B11	0,478,363 A2	4/1/92	EPO					
B12	DE 43 38 944 A1	5/18/95	Germany					
B13	WO 93/08823	5/13/93	PCT					
B14	WO 95/14714	6/1/95	PCT					
B15	WO 95/28426	10/26/95	PCT					
B16	WO 96/00574	1/11/96	PCT					
B17	WO 96/00730	1/11/96	PCT					
B18	94/0435	1/21/94	South Africa					
B19	94/2124	3/25/94	South Africa					
B20	94/9017	11/14/94	South Africa					
B21	95/32710	12/7/95	PCT					

EXAMINER


DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SO3078/4	APPLICATION NO.: 10/016,146
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Cunningham, et. al.	
(Use several sheets if necessary)		Filed: 12/10/01	Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
C1	Carter, et. al., <i>Chemotherapy of Cancer</i> , Sec. Ed., John Wiley & Sons, NY, NY, (1981) 107-108	
C2	Pommier, et. al., <i>HIV-1 Integrase as Target for Antiviral Drugs</i> , Antiviral Chemistry & Chemotherapy, Vol. 8 (No. 6) (1997) 463-483	
C3	Nicklaus, et. al., <i>HIV-1 Integrase Pharmacophore: Discovery of Inhibitors Through Three-Dimensional Database Searching</i> , J. Med. Chem., 7 th ed., American Chemical Society, v. 40 (1997) 920-929	
C4	Hong, et. al., <i>Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching</i> , J. Med. Chem., American Chemical Society, v. 40, (1997) 930-936	
C5	Fields, <i>Integrins: Cell Adhesion Molecules in Cancer</i> , Exp. Opin. Ther. Patents, Ashley Publications Ltd., Vol. 8 (No. 6), (1998) 633-644	
C6	N.A., Derwent Abstract #00305 K/01	
C7	N.A., Derwent Abstract #57918 B/18	
C8	N.A., Derwent Abstract #77105 E/37	
C9	N.A., Derwent Abstract #87-009150/02	
C10	N.A., Derwent Abstract #87-065042/10	
C11	N.A. Derwent Abstract #89-055466/08	
C12	N.A. Derwent Abstract #89-349943/48	
C13	N.A. Derwent Abstract #92-398070/48	
C14	N.A. Derwent Abstract #93-060253/08	
C15	N.A. Derwent Abstract #93-08363/11	
C16	N.A. Derwent Abstract #93-127579/16	
C17	Adamis, <i>Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy</i> , American Journal of Ophthalmology, Vol 118 (1994) 445-450	
C18	Brooks, et. al., <i>Requirement for Vascular Integrin $\alpha_1\beta_3$ for Angiogenesis</i> , Science, Vol 264 (1994) 569-571	
C19	Clyman, et. al., <i>β_1 and β_3 Integrins Have Different Roles in the Adhesion and Migration of Vascular Smooth Muscle Cells on Extracellular Matrix</i> , Experimental Cell Research, Vol 200, (1992)272-284	
C20	Liaw, et. al., <i>The Adhesive and Migratory Effects of Osteopontin Are Mediated Via Distinct Cell Surface Integrins : Role of $\alpha_1\beta_3$ in Smooth Muscle Migration to Osteopontin in Vitro</i> , Journal of Clinical Investigation, Vol. 95 (1995) 713-724	
C21	Peacock, et. al., <i>Angiogenesis Inhibition Suppresses Collagen Arthritis</i> , Journal of Experimental Medicine, Vol. 175 (1992) 1135-1138	
C22	Seftor, et. al., <i>Role of the $\alpha_1\beta_3$ Integrin in Human Melanoma Cell Invasion</i> , Proceedings of the National Academy of Sciences U.S.A., Vol. 89 (1992) 1557-1561	
C23	Schnur, et. al., <i>N-(5-Fluorobenzothiazo-2-yl)-2-guanidinothiazone-4-carboxamide. A Novel, Systemically Active Antitumor Agent Effective Against 3LL Lewis Lung Carcinoma</i> , Journal of Medicinal Chemistry, Vol. 34 (3) (1991) 914-918	
C24	Schnur, et. al., <i>Quantitative Structure-Activity Relationships of Antitumor Guanidinothiazolecarboxamides with Survival Enhancement for Therapy in the 3LL Lewis Lung Carcinoma Model</i> . Journal of Medicinal Chemistry, Vol. 34 (7) (1991) 1975-1982	



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: SO3078/4	APPLICATION NO.: 10/016,146
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		INVENTOR: Cunningham, et. al.	
		Filed: 12/10/01	Group: 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C25	Smith, et. al., <i>Interactions of Integrins $\alpha_v\beta_3$ and GlycoProtein llb-llla with Fibrinogen</i> , Journal of Medicinal Chemistry, Vol. 265 (21) (1990) 12267-12271
C26	White, <i>Integrins as Virus Receptors</i> , Current Biology, Vol 3 (9) (1993) 596-599 9
C27	Yue, <i>Osteopontin-Stimulated Vascular Smooth Muscle Cell Migration is Mediated by β_3 Integrin</i> , Experimental Cell Research, Vol. 214, (1994) 459-464
C28	Brooks, et. al., <i>Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels</i> , Cell, Vol. 79 (1994) 1157-1164
C29	Choi, et. al., <i>Inhibition of Neointimal Hyperplasia by Blocking $\alpha_v\beta_3$ Integrin with a Small Peptide Antagonist GopenGRDSPCA</i> , Journal of Vascular Surgery, Vol. 19 (1) 125-133

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)